Company intelligence / Profile preview

Nkure Therapeutics

Bangalore, Karnataka, India
Ownership
Private
Development stage
Other
01

Overview

Nkure Therapeutics has developed a laboratory-scale NK cell immunotherapy platform, secured exclusive licenses to CAR and related technologies, and is co-developing CRISPR-edited NK cell therapies with CRISPR Therapeutics. The company is preclinical with no reported clinical trial results as of mid-2025.

Therapeutic areas
OncologyInfectious Diseases
Modalities
NK cell therapyCell therapyGene therapy
Industry
Biotech
02

Partnerships

CRISPR Therapeutics

Beyond the preview

Go deeper on Nkure Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nkure Therapeutics.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call